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Purpose: Although the expression of microRNAs (miRNAs) in retinal pigment epithelial
(RPE) cells undergoing epithelial-mesenchymal transition (EMT) is involved in thepatho-
genesis of proliferative vitreoretinopathy (PVR), its expression in the vitreous of patients
with primary retinal detachment (RD) and different PVR grading has not yet been inves-
tigated. We assessed the expression of miRNAs in the vitreous humor (VH) of patients
diagnosed with RD and different grading of PVR.
Methods: The VH was extracted from the core of the vitreous chamber in patients who
had undergone standard vitrectomy for primary RD. RNA was extracted and TaqMan
Low-Density Arrays (TLDAs) were used formiRNAprofiling thatwas performedby single
TaqMan assays. A gene ontology (GO) analysis was performed on the differentially
expressed miRNAs.
Results:A total of 15 eyeswith RD, 3 eyes for eachgradeof PVR (A, B, C, andD) and3 from
unaffected individuals, were enrolled in this prospective comparative study. Twenty
miRNAs were altered in the comparison among pathological groups. Interestingly, the
expression of miR-143-3p, miR-224-5p, miR-361-5p, miR-452-5p, miR-486-3p, and miR-
891a-5p increased with the worsening of PVR grading. We also identified 34 miRNAs
showing differential expression in PVR compared to control vitreous samples. GO analy-
sis showed that the deregulated miRNAs participate in processes previously associated
with PVR pathogenesis.
Conclusions: The present pilot study suggested that dysregulated vitreal miRNAs may
be considered as a biomarker of PVR and associated with the PVR-related complications
in patients with RD.
Translational Relevance: The correlation between vitreal miRNAs and the pathological
phenotypes are essential to identify thenovelmiRNA-basedmechanismsunderlying the
PVR disease that would improve the diagnosis and treatment of the condition.
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tvst.arvojournals.org | ISSN: 2164-2591 1
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Downloaded from tvst.arvojournals.org on 05/25/2020
MicroRNAs and Proliferative Vitreoretinopathy TVST | May 2020 | Vol. 9 | No. 6 | Article 23 | 2
Introduction
Proliferative vitreoretinopathy (PVR) is a multifac-
torial and complex clinical syndrome common to a
variety of clinical disorders, including retinal detach-
ment (RD).1 The frequency of PVR remains largely
unchanged in primary RD, with the incidence ranging
from 5.1% to 11.7% of all rhegmatogenous RDs,
and it is believed to be the leading cause of RD
surgery failure accounting for 75% of retinal redetach-
ment surgeries.1,2 PVR is characterized by pre-,
sub-, or intra-retinal fibrosis (scarring) that grows
on the membrane surface of the detached retina
and posterior hyaloids causing foreshortening of the
retina, traction, and recurrent detachment mostly
within the first 6 to 8 weeks after surgery.1 Typically,
PVR with recurrent RDs requires additional surgi-
cal interventions and is associated with poor visual
recovery.2–8
Although the pathogenesis is not elucidated,8–10
previous studies suggested that the epithelial-
mesenchymal transition (EMT)11–13 of the retinal
pigment epithelial (RPE) cells and the inflammatory
response-associated pathways might be involved in the
pathogenesis underlying PVR.13–18 However, to date,
there are no effective medications for the prevention
and treatment of PVR and an urgent approach is
demanded.19–22
MicroRNAs (miRNAs) are small endogenous
noncoding RNAs that negatively regulate gene expres-
sion within all cell types. The miRNAs play a key
role in cellular physiology and various biological
pathways in specific cell types and tissues.23–25 Previ-
ously, abnormal miRNA expression has been reported
in cellular and extracellular compartments with respect
to cancers and other diseases, such as cardiac, neuro-
logical, and ocular,26–32 and previous studies have
shown that specific miRNAs induce/inhibit EMT in
other fibroblast-like cells.33–35
The aberrant expression of miRNAs in RPE cells
undergoing EMT is involved in the pathogenesis of
PVR.36–44 Takayama et al. demonstrated the involve-
ment of miR-148a-3p in the regulation of migra-
tion ability of RPE cells,36 and the same function
was reported by Wang et al. for miR-182.44 Never-
theless, the characteristics and the distinct role of
miRNAs in PVR and their expression in the vitreous of
patients with primary RD with different PVR grading
have been poorly investigated, with only few papers
published.37,45
In this pilot study, 754 miRNAs were subjected to
real-time PCR expression profiling in order to identify
the differentially expressed miRNAs in the vitreous of
patients diagnosed with primary RD and a different
grading of PVR.
Materials and Methods
This prospective pilot study included consecutive
eyes undergoing pars plana vitrectomy for the treat-
ment of primary RD with and without PVR.
All surgery procedures were performed by the same
surgeon at the Department of General Ophthalmol-
ogy, Medical University of Lublin (Poland) between
January and June 2018.
The exclusion criteria were as follows: patients with
diabetes mellitus, known rheumatic and autoimmune
diseases, systemic treatments involving corticosteroids
or immunomodulatory drugs, vitreous hemorrhage,
uveitis, glaucoma, or any concomitant retinal pathol-
ogy, a previous ocular trauma, a diagnosed eye tumor,
or who had undergone intraocular surgery or treat-
ment within 6 months after the diagnosis of RD. These
systemic or ocular comorbidities might influence the
mechanisms underlying ocular fibrosis.
The present patient study was approved by the
Ethics Committee of the Medical University of Lublin
(KE-0254/277/2019) in compliance with the Decla-
ration of Helsinki. Written informed consent was
obtained from each participant allowing the use of
their biological materials and clinical data.
PVR Grading and Patient Grouping
Based on the severity of the PVR, the patients were
classified into four stages: A (minimal), B, C, and D
(massive) according to the “Retina Society Terminol-
ogy Committee.”46
As proposed by Zandi et al.,18 in the current study,
the risk of developing postoperative PVR in patients
with RD with low PVR severity (grades A or B) or
without PVRwas found to be similar. Thus, PVRgrade
C was included until three quadrants were seen with
visible PVR membrane formation. However, the sever-
ity was grade D if all four quadrants were affected.
Because advanced PVR is challenging for accurate
grading, all patients underwent indirect fundus
ophthalmoscopy with scleral indentation prior to
surgery. Two masked expert retinal specialists (M.D.T.
and K.N.) investigated the fundus and assigned the
PVR score; the discrepancies were resolved by a third
investigator (R.R.).
Control vitreous samples (CTRL) were obtained
from patients who underwent vitrectomy for primary
symptomatic idiopathic floaters.
Downloaded from tvst.arvojournals.org on 05/25/2020
MicroRNAs and Proliferative Vitreoretinopathy TVST | May 2020 | Vol. 9 | No. 6 | Article 23 | 3
Handling of Vitreous Fluid Samples
A 3-port 23-gauge vitrectomy was performed on
all the patients while they were under local anesthe-
sia. The Resight 700 (Carl Zeiss Meditec AG, Jena,
Germany) wide-angle viewing system or the Binocular
Indirect Ophthalmo-Microscope wide-angle viewing
system (BIOM; Oculus Inc., Wetzlar, Germany) was
used. Sclerotomy was carried out at 3.5 mm parallel
to the limbus at 30°.33 Then, 2 mL vitreous sample
extracted from the core of the vitreous cavity before
vitrectomy was subjected to centrifugation at 700 × g
for 10 minutes to exclude any circulating cells or debris.
The pellets were stored at −80°C until further analysis.
miRNA Expression Profiling in Vitreous
Humor by TLDAs
Total RNA was isolated from 400 μL vitreous
humor (VH) using miRNeasy Mini Kit (Qiagen),
according to the manufacturer’s protocol. The amount
and purity of RNA were assessed using NanoDrop
1000 Spectrophotometer (Thermo Fisher Scientific).
The expression of 754 miRNAs was evaluated by real-
time PCR using the TaqMan Low-Density Arrays
(TLDAs) from 15 VH samples (3 patients for each
grade of the disease and 3 unaffected individuals).
About 30 ng of RNA was transcribed using TaqMan
MicroRNA Reverse Transcription Kit and Megaplex
RT Primers Human Pool A version 2.1 and Pool
B version 3.0 (Thermo Fisher Scientific) and pre-
amplified by TaqMan PreAmp Master Mix Kit and
Megaplex PreAmp Primers using the Human Pool A
version 2.1 and Pool B version 3.0 (Thermo Fisher
Scientific). The products were loaded in TaqMan
Human MicroRNA Array version 3.0 A and B
(Thermo Fisher Scientific), and the real-time PCR
reactions were carried out on a 7900 HT Fast
Real-Time PCR System (Applied Biosystems) using
TaqMan Universal Master Mix II without uracil-
DNA N-glycosylase UNG (Thermo Fisher Scien-
tific), according to the manufacturer’s instructions.
Expression fold changes of differentially expressed
(DE) miRNAs were calculated by applying the 2−Ct
method.47
Statistical Analysis
The expression data were subjected to signifi-
cance analysis of microarrays (SAMs), computed by
Multi Experiment Viewer version 4.8.1 (http://mev.
tm4.org) using the multiclass tests and 1-way analysis
of variance (ANOVA) test (P< 0.05) amongCts. The
endogenous control was selected based on the global
median normalization method, which allowed us to
identify the miRNAs with the most stable expression
in the samples.24 We used three different endogenous
controls for each TLDA panel (comparisons among
PVR stages: panel A: miR-197, U6, and median of
Cts; panel B: miR-1285, U6, and median of Cts;
PVR versus CTRL: panel A: median of Cts, miR-
146a-5p, and miR-28-3p; panel B: median of Cts,
miR-625-3p, and miR-30e-3p; A + B versus CTRL:
panel A: miR-29a-3p, miR-20b-5p, and miR-24-3p;
panel B: miR-30-3p, median of Cts, and miR-30a-
5p; C + D versus CTRL: panel A: miR-17-5p, miR-
320a, and miR-28-3p; panel B: U6, median of Cts,
and miR-30e-3p), considering differentially expressed
only those miRNAs that were deregulated according to
two endogenous control. Gene ontology (GO) analysis
was performed on the DE miRNAs through DIANA-
miRPath version 3.0 (http://snf-515788.vm.okeanos.
grnet.gr/).48
Results
miRNA Expression Profile in the VH of
Patients With PVR
The expression of 754 miRNAs in the VH of 15
patients, including 3 patients for each grade of the
disease (A, B, C, and D) and 3 unaffected individuals,
was analyzed by TLDA profiling. When comparing the
different disease stages, statistical analysis of profiling
results was performed by grouping A and B samples,
characterized by absent or minimal proliferation. We
identified 20 miRNAs with altered expression in one
or more pathological groups, according to at least two
out of three endogenous controls. Specifically, let-7b-
5p, miR-100-5p, miR-1300, miR-143-3p, miR-152-3p,
miR-16-5p, miR-19b-3p, miR-203a, miR-21-5p, miR-
218-5p, miR-223-5p, miR-224-5p, miR-30b-5p, miR-
335-5p, miR-340-5p, miR-361-5p, miR-452-5p, miR-
486-3p, miR-891a-5p, and miR-99a-5p showed differ-
ential expression in different comparisons (Table 1,
Fig. 1).
Interestingly, miR-143-3p, miR-224-5p, miR-
361-5p, miR-452-5p, miR-486-3p, and miR-891a-5p
expression aggravated the disease, suggesting a possi-
ble application of these miRNAs as biomarkers for
PVR (Fig. 2).
In addition, we compared the vitreous of patients
with PVR to unaffected individuals. This analysis was
performed in three steps, grouping all PVR samples,
samples from stages A and B, and samples from stages
C and D, respectively. This additional analysis showed
the deregulation of different sets of miRNAs in each
comparison (Fig. 3, Tables 2, 3, 4).
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Table 1. TLDA Profiling Showed the Differential Expression of 20 MiRNAs in the Different Comparisons
ANOVA C Versus A + B D Versus A + B D Versus C
miRNA P Value FC P Value FC P Value FC P Value
let-7b-5p 0.022 −16.85 0.021 3.76 0.33 28.76 0.009
miR-100-5p 0.003 −13.21 0.008 4.9 0.06 24.76 0.001
miR-1300 0.003 12.59 0.005 −3.45 0.1 −23.53 0.001
miR-143-3p < 0.0001 9.93 0.0005 26.41 < 0.0001 2.65 0.08
miR-152-3p 0.01 −5.28 0.1 12.03 0.024 33.68 0.003
miR-16-5p 0.026 −4.94 0.22 16.77 0.035 32.68 0.009
miR-19b-3p 0.019 −2.79 0.1 3.59 0.049 10.03 0.006
miR-203a 0.033 −5.64 0.13 8.95 0.07 30.51 0.011
miR-21-5p 0.011 1.19 0.83 22.15 0.004 18.56 0.013
miR-218-5p < 0.0001 −1.45 0.27 15.28 < 0.0001 22.3 < 0.0001
miR-223-5p 0.016 −11.65 0.008 1.14 0.85 13.3 0.013
miR-224-5p 0.003 2.46 0.38 36.26 0.001 28.97 0.01
miR-30b-5p 0.039 −26.91 0.017 −1.02 0.98 26.33 0.034
miR-335-5p 0.025 −8.72 0.033 3.09 0.22 26.99 0.009
miR-340-5p 0.031 −2.91 0.25 8.36 0.039 24.38 0.012
miR-361-5p 0.003 4.82 0.26 36.81 0.001 18.78 0.014
miR-452-5p 0.0002 19.17 0.001 33.38 < 0.0001 5.6 0.07
miR-486-3p 0.011 6.06 0.08 32.98 0.004 5.43 0.14
miR-891a-5p 0.002 2.46 0.4 35.38 0.0007 21.01 0.005
miR-99a-5p 0.001 −21.67 0.002 3.82 0.1 32.84 0.0006
The average FC and the P value derived from multiple comparisons for each miRNA are shown. The P value of the ANOVA
test between all groups is also shown. Significant P values are highlighted in bold.
FC, fold change.
Figure 1. Heatmap showing the expression of miRNAs analyzed through TLDA profiling. The miRNA expression is represented as relative
quantity (RQ), calculated with respect to the average of Cts of all the analyzed samples.
GO analysis
GO analysis was performed on the six miRNAs
showing increased expression with PVR worsen-
ing. GO results showed that miR-143-3p, miR-
224-5p, miR-361-5p, miR-452-5p, miR-486-3p, and
miR-891a-5p participate in the biological processes
involved in PVR pathogenesis, such as cell cycle
regulation, adhesion to the extracellular matrix
(ECM), and regulation of actin cytoskeleton10,49–51
(Fig. 4).
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Figure 2. Boxplots showing the expression ofmiR-143-3p,miR-224-5p,miR-361-5p,miR-452-5p,miR-486-3p, andmiR-891a-5p in the three
pathological groups. **P value versus A + B < 0.005; ***P value versus A + B < 0.0005; #P value versus C < 0.05.
Figure 3. Heatmap showing the expression ofmiRNAs analyzed through TLDAprofiling in the comparisons of patientswith PVR compared
to unaffected individuals. The miRNA expression is represented as relative quantity (RQ), calculated with respect to the average of Cts of
all the analyzed samples.
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Figure 4. PVR-related Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways regulated bymiR-143-3p,miR-224-5p,miR-361-5p,
miR-452-5p,miR-486-3p, andmiR-891a-5p. TheX-axis represents the
-log10 of the P value for each pathway.
Similarly, GO analysis was performed on miRNAs
showing altered expression in the three comparisons
with respect to unaffected individuals. Again, results
showed the involvement of DE miRNAs in biological
processes previously associated with PVR pathogene-
sis10,49–51 (Fig. 5).
Discussion
The current pilot study identified altered expression
of 20 miRNAs in one or more pathological groups
of the VH of patients with primary RD and a differ-
ent grading of PVR. The analysis revealed that the
expression of six miRNAs (miR-143-3p, miR-224-
5p, miR-361-5p, miR-452-5p, miR-486-3p, and miR-
891a-5p) increased with the worsening of the disease;
similarly, expression profiles of vitreal miRNAs in
patients with PVR were compared with unaffected
individuals, showing that several miRNAs may be used
as molecular biomarkers for the disease. According
to the GO analysis, these miRNAs participated in
the biological processes involved in PVR pathogene-
sis, such as cell cycle regulation, adhesion to ECM, and
regulation of actin cytoskeleton.
PVR is the main cause of retinal surgical failure.52
The PVR is primarily treated using vitrectomy, system-
atic peeling and dissecting epiretinal membranes,
and retinal tamponade with silicone oil or gas.53–55
However, recurrent traction proliferation causes
postsurgical retinal re-detachment.52
Currently, the adjuvant therapy for the treatment
of PVR includes agents, such as anti-inflammatory
drugs, growth factor inhibitors, and antioxidants.2,22
Recently, a series of low-dose methotrexate injections
seem to be beneficial for treating complex retinal
detachment caused by PVR,56,57 however, all these
therapies are quite elusive and an urgent approach is
demanded. Thus, additional studies are essential to
Table 2. ThemiRNAs ShowingAltered Expression in all
Patients With PVR Compared to Unaffected Individuals
PVR versus CTRL




















The average FC and the P value derived from the t-test are
shown for each miRNA.
FC, fold change.
Table 3. The MiRNAs Showing Altered Expression in
Stage A + B Patients Compared to Unaffected Individ-
uals
A + B versus CTRL














The average FC and the P value derived from the t-test are
shown for each miRNA.
FC, fold change.
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Figure 5. PVR-related Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways regulated by miRNAs showing altered expression in
the comparisons PVR versus CTRL, A+ B versus CTRL, and C+Dversus CTRL. The X-axis represents the -log10 of the P value for each pathway.
elucidate the mechanisms regulating the early phases
and development of PVR.
The development and progression of fibrotic
lesions, including proliferative diabetic retinopathy
(PDR) and PVR are caused by EMT. In addition,
wound healing and stimulation of inflammatory
cytokines lead to EMT, thereby forming pre- or
subretinal fibrous membranes.1
Importantly, RPE cells play a vital role in the devel-
opment of fibrosis on the retina and constitute the
largest cellular component of epiretinal membranes
in addition to hyalocytes, retinal Müller glial cells,
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Table 4. The MiRNAs Showing Altered Expression in



















The average FC and the P value derived from the t-test are
shown for each miRNA.
FC, fold change.
fibroblasts, and macrophages.1 RPE cells are usually
quiescent in healthy condition. Interestingly, trauma or
intraocular diseases damage the RPE or cause retinal
detachment. The subsequent repair triggers the loss of
cell-cell contact in RPE cells, and, also, the epithelial
cells are stimulated to proliferate into motile fibroblast-
like cells.1
Initially, the transforming growth factor-β (TGF-
β), promotes various types of fibrotic diseases,
including PVR and PDR.1,54,55,58–64 Subsequently,
trans-differentiated RPE cells migrate into the inner
retinal layers or vitreous body, produce ECM compo-
nents, and transform into fibroblast-like cells. This
phenomenon results in the formation of epiretinal
membranes that contract and cause retinal detachment
as well as visual impairment.1,54,55,58–63
The miRNAs regulate the complex physiologi-
cal and pathological processes, such as embryogene-
sis, organ development, oncogenesis, and angiogene-
sis.65,66
Intriguingly, miRNAs are positive or negative
regulators of EMT that target the multiple compo-
nents of the EMTmachinery and exacerbate their criti-
cal roles in TGF-β2-induced EMT in human RPE
cells.37,67 In addition, miRNAs regulate fibrosis in
several organs.68
Although the role of miRNAs in PVR is not yet
clarified, no study has investigated their expression in
the vitreous of patients with RD with different PVR
grades. Nevertheless, most of the miRNAs showing
altered expression in the inter-stage comparisons has
been previously associated with other ocular diseases,
as shown in Table 5.31,37,69–88
The only study that assessed the miRNA expres-
sion in the VH of patients with PVR diseases, includ-
ing PDR, was performed by Usui-Ouchi and co-
workers.37 These authors used quantitative real time
(qRT)-PCR to identify miR-21-5p in the VH as a
potential disease-modifying agent. Furthermore, the
expression of miR-21-5p is enhanced by the disease-
associated expression of TGF-β2 and/or high glucose
conditions, which could be crucial in the fibropro-
liferative response of RPE cells during the develop-
ment of retinal fibrotic disorders. In addition, the cell
migration and proliferation of RPE cells was increased
markedly. Also, the level of miR-16-5pwas upregulated
in the vitreous of the same eyes. Consistent with this
report, the current data showed an increased expres-
sion of miR-21-5p and miR-16-5p in vitreous patients
with PVR.
Among the miRNAs previously associated with
EMT, miR-223-5p was shown to be upregulated after
TGF-β treatment of RPE cells, whereas all the other
differentially expressed miRNAs (except for miR-1300
and miR-891a-5p) regulate the EMT in cancer.40
Further, several studies reported the involvement of
differentially expressedmiRNAs in angiogenesis in eye-
associated diseases (let-7b-5p, miR-152-3p, miR-21-
5p, miR-218-5p, and miR-30b-5p)37,69,74,78,79,81,82,89
or various cancer models (miR-891a-5p).90 Similarly,
among differentially expressed miRNAs, 12 out of 20
(let-7b-5p, miR-152-3p, miR-16-5p, miR-19b-3p, miR-
203a, miR-21-5p, miR-224-5p, miR-335-5p, miR-340-
5p, miR-486-3p, miR-891a-5p, and miR-99a-5p) are
associated with fibrosis regulation.91–102
The present pilot study, which we believe has been
done for the first time, described a putative corre-
lation between miRNAs and fibrotic phenomena in
patients with PVR following RD. Nevertheless, the
present study has some limitations: the low number
of samples and the modality of grading of PVR. The
grading of PVR, even if assigned based on the classifi-
cation system established by the “Retina Society Termi-
nology Committee,”46 is still conducive to a subjective
clinical choice of the retinal disease specialists and not
on an objective diagnostic method. Despite the small
number of patients enrolled in this pilot study, our
results suggest that vitreal miRNAs could be consid-
ered PVR biomarkers. Needless to say, further studies
on larger cohorts, possibly including vitreous samples
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Table 5. Previous Studies Reporting the Association of DE miRNAs Deregulated in Inter Stage Comparisons With
Ocular Diseases
miRNA Disease Reference
let-7b-5p Diabetic retinopathy, age-related cataract 69,70
miR-143-3p Glaucoma, human subconjunctival fibrosis, oxygen-induced retinopathy 71–73
miR-152-3p Diabetic retinopathy, age-related macular degeneration, oxygen-induced retinopathy 73–75
miR-16-5p Proliferative vitreoretinopathy, glaucoma, age-related cataract 37,76,77
miR-19b-3p Idiopathic epiretinal membrane and macular hole 31
miR-21-5p Proliferative vitreoretinopathy, ischemic retina, diabetic retinopathy 37,78,79
miR-223-5p Noninfectious uveitis 80
miR-224-5p Uveal melanoma 81
miR-30b-5p Diabetic retinopathy 82
miR-335-5p Age-related macular degeneration 83
miR-340-5p UVB-mediated retinal pigment epithelium cell damage 84
miR-361-5p Age-related macular degeneration, retinoblastoma 85,86
miR-452-5p Cataract 87
miR-486-3p Retinoblastoma 88
from unaffected individuals, will be useful to validate
miRNAs as disease biomarkers.
Conclusions
In conclusion, a set of DE miRNAs were identi-
fied in PVR conditions. Despite the small cohort, our
study suggests that specific miRNAs could be consid-
ered good candidates as biomarkers for PVR. Further-
more, elucidating the role of other miRNAs in EMT in
RPE cells in vitro and in PVR in vivo would provide an
in-depth insight into the EMT-related gene expression.
Thus, additional studies on the correlation between
vitreal miRNAs and the pathological phenotypes are
essential to identify the novel miRNA-based mecha-
nisms underlying the PVR disease that would improve
the diagnosis and treatment of the condition.
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